CDNA Caredx Inc

$CDNA Im still not sure what this company is or why I own it. Seems like thats the recipe for success in this market

$CDNA Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.70 up 150.00% YoY • Reported revenue of $139.36M up 39.28% YoY

The 52-week relative-strength high list is dominated by healthcare stocks this morning: $CDNA $EXEL $GILD $LLY $VRTX etc.

$CDNA reports Oct 29, the first full quarter under expanded Medicare coverage of up to 6 AlloSure Kidney tests in year 1. Test volume is the cleanest read on demand. Last quarter it grew 17%

Earnings beat that actually moved the needle imo $CDNA printed 70 cents versus a 24 cent estimate, revenue 139.36 million up about 39% from a year ago, and premarket has it near 77 off a 71.52 close. Transplant testing doing real numbers, not just a story

$CDNA weekly Darvas: 4-week sideways consolidation 61.19-72.71 (weeks of 9/28 to 10/19). Q3: EPS $0.70 vs $0.24 est, revenue ~$139M (+39% y/y), FY26 guide raised to ~$525M. Oct 30 close 87.41 (+22.2%) on ~2.7x avg volume. Box was the timing, the beat and raise was the fuel. Confirm: holds above 72.71. First warning: back inside the box. Full invalidation: weekly close below 61.19. Educational only, not investment advice.

$CDNA Bullish on the print, not on the tape — CareDx doubled adjusted EBITDA margin to 22% and guided to $520–530M revenue, which is a genuine business-model change. But it ran to +26% intraday on only 1.9× normal volume while 13.6% of the float is still short and the Nov-20 puts already out-number the calls, so the easy money was made in the gap.

$CDNA now approaching best case +275% upside target. Adding another +20% today. Quite a few happy members.

$CDNA has a bunch of shorts-- As of October 15, 2026, approximately 13.30% of CareDx, Inc. (CDNA) public float is sold short, according to data from MarketBeat. Key Short Interest Metrics for CareDx (CDNA) Short Percent of Float: 13.30% (as of October 15, 2026)

$CDNA 16:01 [CDNA] Reports Q3 $0.70 v $0.28 y/y, Rev $139M v $72M y/y; Guides FY26 well ahead of consensus Raises FY26 Rev $520.0-530.0M v $495ME (prior: $490-500M)Raises FY26 adj EBITDA $90.0-100.0M (prior: $66-78M)Adj EBITDA $30.5M v $15.3M y/y ttn

$CDNA reports earnings today after the close. I’m bullish heading into the report: CDNA has beaten EPS estimates in 6 of its last 8 reports, according to Stock Meadow.